| Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy TN Gide, C Quek, AM Menzies, AT Tasker, P Shang, J Holst, J Madore, ... Cancer cell 35 (2), 238-255. e6, 2019 | 772 | 2019 |
| Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade IG House, P Savas, J Lai, AXY Chen, AJ Oliver, ZL Teo, KL Todd, ... Clinical Cancer Research 26 (2), 487-504, 2020 | 525 | 2020 |
| Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma TN Gide, JS Wilmott, RA Scolyer, GV Long Clinical Cancer Research 24 (6), 1260-1270, 2018 | 415 | 2018 |
| CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti … J Edwards, JS Wilmott, J Madore, TN Gide, C Quek, A Tasker, A Ferguson, ... Clinical Cancer Research 24 (13), 3036-3045, 2018 | 413 | 2018 |
| Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1–based immunotherapy SY Lim, JH Lee, TN Gide, AM Menzies, A Guminski, MS Carlino, EJ Breen, ... Clinical Cancer Research 25 (5), 1557-1563, 2019 | 342 | 2019 |
| Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients H Kakavand, LA Jackett, AM Menzies, TN Gide, MS Carlino, RPM Saw, ... Modern Pathology 30 (12), 1666-1676, 2017 | 219 | 2017 |
| Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients H Lee, C Quek, I Silva, A Tasker, M Batten, H Rizos, SY Lim, T Nur Gide, ... Oncoimmunology 8 (2), e1537581, 2019 | 88 | 2019 |
| Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients TN Gide, IP Silva, C Quek, T Ahmed, AM Menzies, MS Carlino, RPM Saw, ... Oncoimmunology 9 (1), 1659093, 2020 | 86 | 2020 |
| Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites JW Conway, RV Rawson, S Lo, T Ahmed, IA Vergara, TN Gide, GH Attrill, ... Journal for Immunotherapy of Cancer 10 (9), 2022 | 36 | 2022 |
| Obesity is associated with altered tumor metabolism in metastatic melanoma AW Hahn, AV Menk, DB Rivadeneira, RC Augustin, M Xu, J Li, X Wu, ... Clinical Cancer Research 29 (1), 154-164, 2023 | 24 | 2023 |
| Validation of an accurate automated multiplex immunofluorescence method for immuno-profiling melanoma Z Yaseen, TN Gide, JW Conway, AJ Potter, C Quek, AM Hong, GV Long, ... Frontiers in Molecular Biosciences 9, 810858, 2022 | 20 | 2022 |
| Inter‐and intrapatient heterogeneity of indoleamine 2, 3‐dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment TN Gide, BM Allanson, AM Menzies, PM Ferguson, J Madore, RPM Saw, ... Histopathology 74 (6), 817-828, 2019 | 18 | 2019 |
| Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3+ anti-PD-1-based immunotherapies TN Gide, EC Paver, Z Yaseen, N Maher, N Adegoke, AM Menzies, ... Oncoimmunology 12 (1), 2261248, 2023 | 17 | 2023 |
| Clinical and molecular heterogeneity in patients with innate resistance to anti-pd-1+/− anti-ctla-4 immunotherapy in metastatic melanoma reveals distinct therapeutic targets TN Gide, I Pires da Silva, C Quek, PM Ferguson, M Batten, P Shang, ... Cancers 13 (13), 3186, 2021 | 16 | 2021 |
| Intratumoral CD16+ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA … H Lee, AL Ferguson, C Quek, IA Vergara, I Pires daSilva, R Allen, ... Clinical Cancer Research 29 (13), 2513-2524, 2023 | 15 | 2023 |
| Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies NA Adegoke, TN Gide, Y Mao, C Quek, E Patrick, MS Carlino, SN Lo, ... Journal for ImmunoTherapy of Cancer 11 (10), 2023 | 14 | 2023 |
| Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis KJ Nahar, F Marsh-Wakefield, RV Rawson, TN Gide, AL Ferguson, ... JCI insight 7 (21), 2022 | 10 | 2022 |
| Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach Y Mao, TN Gide, NA Adegoke, C Quek, N Maher, A Potter, E Patrick, ... Journal of Translational Medicine 21 (1), 257, 2023 | 5 | 2023 |
| A biomarker-guided Bayesian response-adaptive phase II trial for metastatic melanoma: The Personalized Immunotherapy Platform (PIP) trial design. SN Lo, TN Gide, M Gonzalez, I Silva, AM Menzies, MS Carlino, ... Journal of Clinical Oncology 40 (16_suppl), TPS9599-TPS9599, 2022 | 2 | 2022 |
| Abstract LB208: Obesity is associated with lower tumor oxidative phosphorylation (OXPhos) in metastatic melanoma (MM) AW Hahn, M Xu, J Li, LE Haydu, MAW Khan, TN Gide, AM Menzies, ... Cancer Research 81 (13_Supplement), LB208-LB208, 2021 | 2 | 2021 |
